Trials / Recruiting
RecruitingNCT06421701
Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus
A Clinical Study of Anti-CD19 CAR-NK Cells in the Treatment of Refractory/Relapsed Systemic Lupus Erythematosus
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single-center, open-label, single-arm trial. The aim of this study is to investigate the safety and efficacy of anti-CD19 CAR-NK cells in patients with refractory/relapsed systemic lupus erythematosus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | anti-CD19 CAR-NK cells | Patients will receive Fludarabine and Cyclophosphamide for lymphodepletion conditioning. Anti-CD19 CAR-NK cells will be infused on Day 0, 3, and 6. |
Timeline
- Start date
- 2024-08-01
- Primary completion
- 2025-08-01
- Completion
- 2026-05-31
- First posted
- 2024-05-20
- Last updated
- 2025-05-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06421701. Inclusion in this directory is not an endorsement.